Biotech Values

[DewDiligence]

Re: GTCB

I concur with Urche. And, yes, the EMEA has 90 days to act on the ATryn review once the clock restarts following receipt of GTCB’s answers.

Regarding an ATryn partnership, the devil is in the details… and the partner. Ideally, GTCB will be able to attract a top-tier European pharma, which would surely be a market-moving event. On the other hand, if the partner is a small-time company no one has ever heard of, don’t expect the stock price to respond favorably.

As stated previously, I’m in GTCB as a long-term investor in a “new paradigm” for biopharmaceuticals. Hence, I am less interested (but not totally disinterested) in what the news flow means for trading opportunities.